Legend is advancing the next generation of cell therapy through a diversified pipeline spanning autologous, allogeneic, and in vivo chimeric antigen receptor therapy (CAR-T) approaches. Building on our commercial experience and leadership with CARVYKTI®, we are focused on expanding patient access and addressing key limitations of the current cell therapy paradigm.
We are actively evaluating multiple targets and indications across hematologic malignancies, solid tumors, and autoimmune diseases.
Our therapeutic candidates are built on three core strengths of the R&D team:
CAR-T cells are genetically engineered T cells that express a chimeric antigen receptor (CAR), which is a hybrid protein containing three parts: a tandem antigen-binding domain of an antibody; a transmembrane domain; and the signal transduction elements of the T cell receptor complex.
The CAR antigen-binding domain seeks out tumor cells that express the target cell surface antigen. Once the CAR finds its target, it sends out molecular signals via its intracellular modules to activate CAR-T cells, resulting in the destruction of the target tumor cells.
Autologous CAR-T, the foundation of Legend’s lead product CARVYKTI®, utilizes a patient’s own T cells to create a personalized treatment. T cells are collected from the patient through a process called leukapheresis and genetically engineered to express a chimeric antigen receptor (CAR) that enables them to recognize and target cancer cells. Once manufactured, the CAR-T cells are infused back into the patient, where they can seek out and destroy tumor cells.
Building on its leadership in autologous CAR‑T, Legend is advancing a pipeline of innovative cell therapies across hematologic malignancies and solid tumors.
Allogeneic cell therapy utilizes healthy donor-derived immune cells to create therapies that can be manufactured in advance and readily available for patient treatment. Unlike autologous therapies, which are derived from a patient’s own cells, allogeneic CAR‑T therapies are generated from pre-screened donor cells engineered to recognize and target cancer cells.
Legend is exploring a range of platforms and cell types to pursue truly “off-the-shelf” cell therapies for patients with hematologic malignancies and autoimmune diseases.
γδ T cells are a subtype of T cells that express a T cell receptor (TCR) composed of γ and δ chains. γδ T cells are distinct from αβ T cells in that they possess both innate immunity, like natural killer (NK) cells, and adaptive immunity, like αβ T cells. In addition, γδ T cells are capable of rapidly infiltrating tissues and can induce major histocompatibility complex (MHC)-independent anti-cancer activity, which makes γδ a promising platform for “off-the-shelf” CAR-T therapy.
Legend Biotech is developing an innovative CAR-T designed to enhance the persistence of CAR-γδ T cells in vivo, as well as a proprietary manufacturing process engineered to generate large-scale CAR-γδ T cells with enhanced cell fitness.
Legend Biotech is developing an allogeneic CAR platform based on natural killer (NK) cells. NK cells serve on the body’s first lines of defense, working against virally infected cells or tumor cells. CAR-NK cells do not need priming and have several mechanisms to elicit responses to tumors that are not limited to the direct release of cytotoxic granules, antibody dependent cellular cytotoxicity (ADCC), CAR-mediated killing or the secretion of inflammatory cytokines.
NK cells can naturally recognize features associated with cellular stress, which facilitates tumor-specific targeting and elimination. When engineered to express CARs, the antitumor effects of NK cells may be even more pronounced.
Our proprietary allogeneic CAR-T technology uses a non-gene-editing approach. Preclinical data indicated that this unique allogeneic CAR-T technology may reduce genomic interference and potentially simplify the chemistry, manufacturing and controls (CMC) process.
In vivo CAR-T is designed to generate CAR-T cells directly within the patient’s body following a single infusion. By eliminating the need for ex vivo cell engineering and manufacturing, this approach has the potential to simplify CAR-T treatment delivery and expand access over time.
Built on Legend’s proprietary TaVec™ platform, these investigational therapies are designed to enhance T cell specificity, transduction efficiency and safety while restricting transduction of non-T cells.
Legend is advancing in vivo CAR-T programs across multiple targets and indications, with the potential to broaden access to cell therapy and support the development of next-generation “off-the-shelf” therapies.
There is no guarantee that the agents discussed will receive health authority approval or become commercially available in any country for the uses being investigated.
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.